Veraxa Biotech Holding AG（简称"Veraxa"）及其合作伙伴Secarna Pharmaceuticals，在抗体寡核苷酸偶联物（AOC）联盟框架下，成功跨越了一项关键研究里程碑。
这一进展标志着双方在创新生物技术领域的协同合作取得了实质性突破。通过将抗体的靶向特异性与寡核苷酸的治疗潜力相结合，该联盟正致力于开发新一代精准医疗方案。此项成果不仅验证了技术平台的可行性，更为主攻难治性疾病的新疗法铺平了道路。
双方团队对此次合作成果表示高度认可，并强调这一里程碑的达成，凝聚了跨学科研究的智慧与不懈努力。展望未来，Veraxa与Secarna将继续深化协作，加速推进项目向临床前及临床阶段转化，以期为患者带来更具变革性的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.